Search bioRxiv⌕ Search

Biology subjects

Wells, R. C.

Publications and source records attributed to Wells, R. C..

3 recordsLinked to original sources

Flux analysis resolves distinct brain uptake and clearance of TfR- and CD98hc-targeting large molecules

Advances in large-molecule delivery across the blood-brain barrier (BBB) by targeting receptors such as transferrin receptor (TfR) or CD98 heavy chain (CD98hc) are shifting the focus from restricted parenchymal access toward brain exposure profiles tailored to therapeutic needs. However, brain concentrations offer only partial insight into delivery mechanisms, as they reflect the net balance of two dynamic processes: flux of molecules entering and leaving the brain, here termed brain uptake and brain clearance, respectively. Here, we establish a generalizable experimental and mathematical modeling framework to resolve these opposing fluxes and demonstrate its application using pharmacokinetic (PK) data from Fc-engineered antibody transport vehicles (ATVs) targeting TfR or CD98hc in humanized knock-in mouse models. First, to directly estimate brain clearance, we engineered anti-ATV antibodies that selectively bind the TV patch to block receptor-mediated brain uptake in vivo. Integrating these measurements with a mechanistic PK model, we then reconstructed brain fluxes of ATV molecules over time across a broad range of receptor affinities. Results demonstrated that TfR-targeting promotes rapid, affinity-dependent brain uptake accompanied by comparatively rapid brain clearance, whereas CD98hc-targeting results in slower brain uptake and prolonged retention. Extending this framework to dual TfR/CD98hc-targeting ATVs suggested that higher observed brain exposure relative to single-receptor formats does not necessarily translate to greater brain delivery: increased exposure was predicted to arise primarily from reduced brain clearance, associated with CD98hc-mediated retention, rather than enhanced uptake through dual-receptor engagement. Together, these results establish a quantitative basis for resolving brain fluxes and engineering brain-targeted biologics for desired therapeutic outcomes.

systems biology↗

Dual targeting of transferrin receptor and CD98hc enhances brain exposure of large molecules

Targeting proteins highly expressed at the blood-brain barrier, including transferrin receptor (TfR) and CD98hc, is a transformative approach enabling more effective brain delivery of biotherapeutics for treatment of neurological diseases. TfR-mediated delivery promotes rapid, high brain uptake, while CD98hc-mediated delivery is slower with more prolonged exposure. Here, we engineer a huIgG Fc domain to bind both TfR and CD98hc to create a dual transport vehicle (TV) platform that drives distinct brain delivery properties. Dual TVs achieve significantly higher brain concentrations than TVs targeting either TfR or CD98hc alone. Modulation of TfR and CD98hc affinities shifts dual TV brain exposure kinetics and biodistribution. Stronger TfR affinity drives faster brain uptake and clearance, while stronger CD98hc affinity yields higher, more sustained concentrations, likely due to CD98hc affinity-dependent reduction in TfR-mediated neuronal internalization. This dual targeting strategy leverages the complementary properties of TfR and CD98hc-mediated brain exposure to increase optionality for brain delivery of biotherapeutics.

neuroscience↗

Targeting Transferrin Receptor to Transport Antisense Oligonucleotides Across the Blood-Brain Barrier

Antisense oligonucleotides (ASO) are promising therapies for neurological disorders, though they are unable to cross the blood-brain barrier (BBB) and must be delivered directly to the central nervous system (CNS). Here, we use a human transferrin receptor (TfR)-binding molecule to transport ASO across the BBB in mice and non-human primates, termed oligonucleotide transport vehicle (OTV). Systemically delivered OTV drives significant, cumulative, and sustained knockdown of the ASO target across multiple CNS regions and all major cell types. Further, systemic OTV delivery enables more uniform ASO biodistribution and knockdown compared to two other clinically relevant ASO delivery routes: a standard, high affinity TfR antibody, or direct ASO delivery to the CSF. Together, our data support systemically delivered OTV as a potential therapeutic platform for neurological disorders. One-Sentence SummarySystemically dosed OTV delivered via TfR1 targeting shows widespread and cumulative target knockdown in the mouse and NHP CNS.

neuroscience↗